MedTrace Logo

Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions

NCT00906087 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-06-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if one of the genes that can cause glaucoma, called myocilin, are associated with larger eye pressure and blood pressure changes in sitting and lying down positions without glaucoma drug treatment and with glaucoma drug treatment with a combination medication called Cosopt® (Merck \& Co., Inc.).

Conditions

Interventions

DRUG

Cosopt (combination eyedrop of dorzolamide and timolol)

One drop in each eye every twelve hours for six weeks

Sponsors & Collaborators

Principal Investigators

  • Sayoko E Moroi, MD, PhD · University of Michigan Department of Ophthalmology and Visual Sciences

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-04
Primary Completion
2012-07-18
Completion
2012-07-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906087 on ClinicalTrials.gov